AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Standard BioTools Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) â€� Form 4 insider transaction filed 06/24/2025

Director Thomas D. Carey reported two equity awards dated 06/20/2025:

  • 94,592 Restricted Stock Units (RSUs) that vest in full on the earlier of 20 Jun 2026 or one day prior to the company’s next annual meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting.
  • 188,490 stock options with a $1.05 exercise price, becoming exercisable in 12 equal monthly installments beginning 20 Jul 2025 and expiring 20 Jun 2035, also subject to continued service.

Following these grants, Carey’s direct beneficial ownership stands at 194,058 common shares. No dispositions were reported; the grants were acquired at $0 cost (for RSUs) and standard option pricing applies upon exercise. The filing does not reference any 10b5-1 trading plan.

The reported awards reflect routine director compensation and do not involve open-market purchases or sales; therefore, immediate dilution or cash impact to shareholders is negligible. Investors may view the transaction primarily as a governance disclosure rather than a signal of near-term fundamentals.

Standard BioTools Inc. (LAB) � Comunicazione Form 4 insider del 24/06/2025

Il direttore Thomas D. Carey ha dichiarato due assegnazioni di azioni datate 20/06/2025:

  • 94.592 Unità Azionarie Vincolate (RSU) che maturano completamente entro il 20 giugno 2026 o il giorno precedente l’assemblea annuale successiva della società, subordinatamente al mantenimento del servizio. Ogni RSU si converte in una azione ordinaria al momento della maturazione.
  • 188.490 opzioni su azioni con prezzo di esercizio di 1,05$, esercitabili in 12 rate mensili uguali a partire dal 20 luglio 2025 e con scadenza il 20 giugno 2035, anch’esse soggette al mantenimento del servizio.

Dopo queste assegnazioni, la posizione diretta di proprietà di Carey ammonta a 194.058 azioni ordinarie. Non sono state segnalate cessioni; le assegnazioni sono state ottenute a costo zero (per le RSU) mentre per le opzioni si applica il prezzo standard al momento dell’esercizio. Nel documento non si fa menzione di alcun piano di trading 10b5-1.

Le assegnazioni riportate rappresentano una normale forma di compenso per il direttore e non coinvolgono acquisti o vendite sul mercato aperto; pertanto, l’impatto immediato in termini di diluizione o liquidità per gli azionisti è trascurabile. Gli investitori possono interpretare la transazione principalmente come un adempimento di trasparenza gestionale piuttosto che come un segnale di cambiamenti fondamentali a breve termine.

Standard BioTools Inc. (LAB) � Presentación del Formulario 4 de transacciones internas el 24/06/2025

El director Thomas D. Carey informó dos adjudicaciones de acciones fechadas el 20/06/2025:

  • 94,592 Unidades de Acciones Restringidas (RSU) que se consolidan en su totalidad a más tardar el 20 de junio de 2026 o un día antes de la próxima junta anual de la empresa, condicionado a la continuidad en el servicio. Cada RSU se convierte en una acción común al consolidarse.
  • 188,490 opciones sobre acciones con un precio de ejercicio de $1.05, que se vuelven ejercitables en 12 cuotas mensuales iguales a partir del 20 de julio de 2025 y expiran el 20 de junio de 2035, también sujetas a la continuidad en el servicio.

Tras estas adjudicaciones, la propiedad directa beneficiaria de Carey es de 194,058 acciones comunes. No se reportaron disposiciones; las adjudicaciones se otorgaron sin costo (para las RSU) y se aplica el precio estándar de las opciones al ejercerlas. La presentación no menciona ningún plan de negociación 10b5-1.

Las adjudicaciones reportadas reflejan una compensación rutinaria para el director y no involucran compras o ventas en el mercado abierto; por lo tanto, el impacto inmediato en dilución o efectivo para los accionistas es insignificante. Los inversores pueden considerar esta transacción principalmente como una divulgación de gobernanza más que como una señal de cambios fundamentales a corto plazo.

Standard BioTools Inc. (LAB) â€� 2025ë…� 6ì›� 24ì� 제출ë� Form 4 ë‚´ë¶€ìž� 거래 ë³´ê³ ì„�

ì´ì‚¬ Thomas D. Careyê°€ 2025ë…� 6ì›� 20ì¼ìž ë‘� ê±´ì˜ ì£¼ì‹ ë³´ìƒ ë‚´ì—­ì� 신고했습니다:

  • 94,592 제한 ì£¼ì‹ ë‹¨ìœ„(RSU)ëŠ� 2026ë…� 6ì›� 20ì� ë˜ëŠ” 회사ì� ë‹¤ìŒ ì—°ë¡€ ì´íšŒ 하루 ì � ì¤� 빠른 시ì ì—� ì „ì•¡ 베스팅ë˜ë©�, ê³„ì† ê·¼ë¬´ ì¡°ê±´ì� 붙어 있습니다. ê°� RSUëŠ� 베스íŒ� ì‹� 보통ì£� 1주로 전환ë©ë‹ˆë‹�.
  • 188,490 ì£¼ì‹ ì˜µì…˜ì¶Ä 행사가ê²� $1.05ë¡�, 2025ë…� 7ì›� 20ì¼ë¶€í„� 12개월ì—� ê±¸ì³ ê· ë“±í•˜ê²Œ 행사 가능해지ë©�, 2035ë…� 6ì›� 20ì� 만료, 역시 ê³„ì† ê·¼ë¬´ ì¡°ê±´ì� ì ìš©ë©ë‹ˆë‹�.

ì� ë³´ìƒ ì´í›„ Careyì� ì§ì ‘ 소유 ì§€ë¶�ì¶Ä 194,058 보통ì£�입니ë‹�. ë§¤ë„ ë‚´ì—­ì¶Ä 없으ë©�, RSUëŠ� ë¬´ìƒ ì·¨ë“, 옵션ì¶Ä 행사 ì‹� 표준 ê°€ê²©ì´ ì ìš©ë©ë‹ˆë‹�. 제출서류ì—는 10b5-1 거래 계íšì—� 대í•� 언급ì� 없습니다.

ë³´ê³ ë� ë³´ìƒì¶Ä ì´ì‚¬ 보수ì� ì¼í™˜ìœ¼ë¡œ, 공개 시장ì—서ì� 매수ë‚� 매ë„와 ê´€ë ¨ì´ ì—†ìœ¼ë¯€ë¡� 주주ì—� 대í•� 즉ê°ì ì¸ í¬ì„ì´ë‚˜ 현금 ì˜í–¥ì¶Ä 미미합니ë‹�. 투ìžìžë“¤ì¶Ä ì� 거래ë¥� 단기ì ì¸ 기본ì � ë³€í™� 신호보다ëŠ� 거버넌스 공개 ì°¨ì›ì—서 í•´ì„í•� ìˆ� 있습니다.

Standard BioTools Inc. (LAB) � Déclaration Formulaire 4 d’initié déposée le 24/06/2025

Le directeur Thomas D. Carey a déclaré deux attributions d’actions datées du 20/06/2025 :

  • 94 592 unités d’actions restreintes (RSU) qui deviennent entièrement acquises au plus tard le 20 juin 2026 ou un jour avant la prochaine assemblée générale annuelle de la société, sous réserve de la continuité du service. Chaque RSU se convertit en une action ordinaire à l’acquisition.
  • 188 490 options d’achat d’actions avec un prix d’exercice de 1,05 $, exerçables en 12 versements mensuels égaux à partir du 20 juillet 2025 et expirant le 20 juin 2035, également sous condition de maintien du service.

Suite à ces attributions, la possession directe effective de Carey s’élève à 194 058 actions ordinaires. Aucune cession n’a été signalée ; les attributions ont été obtenues à coût nul (pour les RSU) et le prix standard s’applique aux options lors de leur exercice. Le dépôt ne fait pas référence à un plan de négociation 10b5-1.

Les attributions déclarées reflètent une rémunération habituelle des administrateurs et n’impliquent pas d’achats ou ventes sur le marché ouvert ; par conséquent, la dilution immédiate ou l’impact en liquidités pour les actionnaires est négligeable. Les investisseurs peuvent considérer cette transaction principalement comme une obligation de transparence de gouvernance plutôt que comme un signal de changements fondamentaux à court terme.

Standard BioTools Inc. (LAB) � Form 4 Insider-Transaktion eingereicht am 24.06.2025

Direktor Thomas D. Carey meldete zwei Aktienzuteilungen vom 20.06.2025:

  • 94.592 Restricted Stock Units (RSUs), die vollständig am frühesten von beiden Terminen freigegeben werden: 20. Juni 2026 oder einen Tag vor der nächsten Hauptversammlung des Unternehmens, vorausgesetzt, der Dienst wird fortgesetzt. Jede RSU wandelt sich bei Freigabe in eine Stammaktie um.
  • 188.490 Aktienoptionen mit einem Ausübungspreis von 1,05 $, die in 12 gleichen monatlichen Raten ab dem 20. Juli 2025 ausübbar sind und am 20. Juni 2035 verfallen, ebenfalls unter der Bedingung fortgesetzter Dienstzeit.

Nach diesen Zuteilungen beträgt Careys direkter wirtschaftlicher Eigentumsanteil 194.058 Stammaktien. Es wurden keine Veräußerungen gemeldet; die Zuteilungen wurden kostenfrei (für RSUs) erlangt, und für die Optionen gilt der Standardpreis bei Ausübung. Die Meldung erwähnt keinen 10b5-1 Handelsplan.

Die gemeldeten Zuteilungen stellen eine routinemäßige Vergütung des Direktors dar und beinhalten keine Käufe oder Verkäufe am offenen Markt; daher ist die unmittelbare Verwässerung oder Auswirkung auf die Liquidität der Aktionäre vernachlässigbar. Investoren können die Transaktion eher als Governance-Offenlegung denn als Signal für kurzfristige fundamentale Veränderungen betrachten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grants; no market-moving information, neutral cash impact.

The Form 4 shows standard annual equity compensation—a sub-$200k share grant and 188k options at $1.05 strike—to a non-executive director. There is no purchase of shares with personal funds, so alignment signals are modest. Because the RSUs vest over one year and options vest monthly over 12 months, share count dilution is both small and spread over time. No other trading activity is disclosed, and ownership after the grant totals 194,058 shares, a minimal percentage of LAB’s outstanding shares. Overall, I consider the filing neutral for valuation and liquidity.

TL;DR: Filing confirms standard board compensation practices; governance compliant.

From a governance standpoint, the company is transparent in disclosing equity incentives. The RSU one-year cliff and 10-year option term with monthly vesting match common small-cap board compensation structures and encourage retention. No 10b5-1 plan was marked, indicating discretionary grants rather than pre-planned trades. There are no red flags such as accelerated vesting or repricing. Hence, I classify the impact as neutral for shareholders.

Standard BioTools Inc. (LAB) � Comunicazione Form 4 insider del 24/06/2025

Il direttore Thomas D. Carey ha dichiarato due assegnazioni di azioni datate 20/06/2025:

  • 94.592 Unità Azionarie Vincolate (RSU) che maturano completamente entro il 20 giugno 2026 o il giorno precedente l’assemblea annuale successiva della società, subordinatamente al mantenimento del servizio. Ogni RSU si converte in una azione ordinaria al momento della maturazione.
  • 188.490 opzioni su azioni con prezzo di esercizio di 1,05$, esercitabili in 12 rate mensili uguali a partire dal 20 luglio 2025 e con scadenza il 20 giugno 2035, anch’esse soggette al mantenimento del servizio.

Dopo queste assegnazioni, la posizione diretta di proprietà di Carey ammonta a 194.058 azioni ordinarie. Non sono state segnalate cessioni; le assegnazioni sono state ottenute a costo zero (per le RSU) mentre per le opzioni si applica il prezzo standard al momento dell’esercizio. Nel documento non si fa menzione di alcun piano di trading 10b5-1.

Le assegnazioni riportate rappresentano una normale forma di compenso per il direttore e non coinvolgono acquisti o vendite sul mercato aperto; pertanto, l’impatto immediato in termini di diluizione o liquidità per gli azionisti è trascurabile. Gli investitori possono interpretare la transazione principalmente come un adempimento di trasparenza gestionale piuttosto che come un segnale di cambiamenti fondamentali a breve termine.

Standard BioTools Inc. (LAB) � Presentación del Formulario 4 de transacciones internas el 24/06/2025

El director Thomas D. Carey informó dos adjudicaciones de acciones fechadas el 20/06/2025:

  • 94,592 Unidades de Acciones Restringidas (RSU) que se consolidan en su totalidad a más tardar el 20 de junio de 2026 o un día antes de la próxima junta anual de la empresa, condicionado a la continuidad en el servicio. Cada RSU se convierte en una acción común al consolidarse.
  • 188,490 opciones sobre acciones con un precio de ejercicio de $1.05, que se vuelven ejercitables en 12 cuotas mensuales iguales a partir del 20 de julio de 2025 y expiran el 20 de junio de 2035, también sujetas a la continuidad en el servicio.

Tras estas adjudicaciones, la propiedad directa beneficiaria de Carey es de 194,058 acciones comunes. No se reportaron disposiciones; las adjudicaciones se otorgaron sin costo (para las RSU) y se aplica el precio estándar de las opciones al ejercerlas. La presentación no menciona ningún plan de negociación 10b5-1.

Las adjudicaciones reportadas reflejan una compensación rutinaria para el director y no involucran compras o ventas en el mercado abierto; por lo tanto, el impacto inmediato en dilución o efectivo para los accionistas es insignificante. Los inversores pueden considerar esta transacción principalmente como una divulgación de gobernanza más que como una señal de cambios fundamentales a corto plazo.

Standard BioTools Inc. (LAB) â€� 2025ë…� 6ì›� 24ì� 제출ë� Form 4 ë‚´ë¶€ìž� 거래 ë³´ê³ ì„�

ì´ì‚¬ Thomas D. Careyê°€ 2025ë…� 6ì›� 20ì¼ìž ë‘� ê±´ì˜ ì£¼ì‹ ë³´ìƒ ë‚´ì—­ì� 신고했습니다:

  • 94,592 제한 ì£¼ì‹ ë‹¨ìœ„(RSU)ëŠ� 2026ë…� 6ì›� 20ì� ë˜ëŠ” 회사ì� ë‹¤ìŒ ì—°ë¡€ ì´íšŒ 하루 ì � ì¤� 빠른 시ì ì—� ì „ì•¡ 베스팅ë˜ë©�, ê³„ì† ê·¼ë¬´ ì¡°ê±´ì� 붙어 있습니다. ê°� RSUëŠ� 베스íŒ� ì‹� 보통ì£� 1주로 전환ë©ë‹ˆë‹�.
  • 188,490 ì£¼ì‹ ì˜µì…˜ì¶Ä 행사가ê²� $1.05ë¡�, 2025ë…� 7ì›� 20ì¼ë¶€í„� 12개월ì—� ê±¸ì³ ê· ë“±í•˜ê²Œ 행사 가능해지ë©�, 2035ë…� 6ì›� 20ì� 만료, 역시 ê³„ì† ê·¼ë¬´ ì¡°ê±´ì� ì ìš©ë©ë‹ˆë‹�.

ì� ë³´ìƒ ì´í›„ Careyì� ì§ì ‘ 소유 ì§€ë¶�ì¶Ä 194,058 보통ì£�입니ë‹�. ë§¤ë„ ë‚´ì—­ì¶Ä 없으ë©�, RSUëŠ� ë¬´ìƒ ì·¨ë“, 옵션ì¶Ä 행사 ì‹� 표준 ê°€ê²©ì´ ì ìš©ë©ë‹ˆë‹�. 제출서류ì—는 10b5-1 거래 계íšì—� 대í•� 언급ì� 없습니다.

ë³´ê³ ë� ë³´ìƒì¶Ä ì´ì‚¬ 보수ì� ì¼í™˜ìœ¼ë¡œ, 공개 시장ì—서ì� 매수ë‚� 매ë„와 ê´€ë ¨ì´ ì—†ìœ¼ë¯€ë¡� 주주ì—� 대í•� 즉ê°ì ì¸ í¬ì„ì´ë‚˜ 현금 ì˜í–¥ì¶Ä 미미합니ë‹�. 투ìžìžë“¤ì¶Ä ì� 거래ë¥� 단기ì ì¸ 기본ì � ë³€í™� 신호보다ëŠ� 거버넌스 공개 ì°¨ì›ì—서 í•´ì„í•� ìˆ� 있습니다.

Standard BioTools Inc. (LAB) � Déclaration Formulaire 4 d’initié déposée le 24/06/2025

Le directeur Thomas D. Carey a déclaré deux attributions d’actions datées du 20/06/2025 :

  • 94 592 unités d’actions restreintes (RSU) qui deviennent entièrement acquises au plus tard le 20 juin 2026 ou un jour avant la prochaine assemblée générale annuelle de la société, sous réserve de la continuité du service. Chaque RSU se convertit en une action ordinaire à l’acquisition.
  • 188 490 options d’achat d’actions avec un prix d’exercice de 1,05 $, exerçables en 12 versements mensuels égaux à partir du 20 juillet 2025 et expirant le 20 juin 2035, également sous condition de maintien du service.

Suite à ces attributions, la possession directe effective de Carey s’élève à 194 058 actions ordinaires. Aucune cession n’a été signalée ; les attributions ont été obtenues à coût nul (pour les RSU) et le prix standard s’applique aux options lors de leur exercice. Le dépôt ne fait pas référence à un plan de négociation 10b5-1.

Les attributions déclarées reflètent une rémunération habituelle des administrateurs et n’impliquent pas d’achats ou ventes sur le marché ouvert ; par conséquent, la dilution immédiate ou l’impact en liquidités pour les actionnaires est négligeable. Les investisseurs peuvent considérer cette transaction principalement comme une obligation de transparence de gouvernance plutôt que comme un signal de changements fondamentaux à court terme.

Standard BioTools Inc. (LAB) � Form 4 Insider-Transaktion eingereicht am 24.06.2025

Direktor Thomas D. Carey meldete zwei Aktienzuteilungen vom 20.06.2025:

  • 94.592 Restricted Stock Units (RSUs), die vollständig am frühesten von beiden Terminen freigegeben werden: 20. Juni 2026 oder einen Tag vor der nächsten Hauptversammlung des Unternehmens, vorausgesetzt, der Dienst wird fortgesetzt. Jede RSU wandelt sich bei Freigabe in eine Stammaktie um.
  • 188.490 Aktienoptionen mit einem Ausübungspreis von 1,05 $, die in 12 gleichen monatlichen Raten ab dem 20. Juli 2025 ausübbar sind und am 20. Juni 2035 verfallen, ebenfalls unter der Bedingung fortgesetzter Dienstzeit.

Nach diesen Zuteilungen beträgt Careys direkter wirtschaftlicher Eigentumsanteil 194.058 Stammaktien. Es wurden keine Veräußerungen gemeldet; die Zuteilungen wurden kostenfrei (für RSUs) erlangt, und für die Optionen gilt der Standardpreis bei Ausübung. Die Meldung erwähnt keinen 10b5-1 Handelsplan.

Die gemeldeten Zuteilungen stellen eine routinemäßige Vergütung des Direktors dar und beinhalten keine Käufe oder Verkäufe am offenen Markt; daher ist die unmittelbare Verwässerung oder Auswirkung auf die Liquidität der Aktionäre vernachlässigbar. Investoren können die Transaktion eher als Governance-Offenlegung denn als Signal für kurzfristige fundamentale Veränderungen betrachten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carey Thomas D.

(Last) (First) (Middle)
C/O STANDARD BIOTOOLS INC.
2 TOWER PLACE, STE 2000

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A 94,592(1) A $0 194,058 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy) $1.05 06/20/2025 A 188,490 (2) 06/20/2035 Common Stock 188,490 $0 188,490 D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Thomas D. Carey by Tomone Tanaka, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs did Director Thomas D. Carey receive according to LAB's latest Form 4?

He was granted 94,592 Restricted Stock Units on 06/20/2025.

What is the exercise price and size of the stock option grant reported for LAB?

Carey received 188,490 options with a $1.05 exercise price.

When do the newly granted LAB stock options become exercisable?

They vest in 12 equal monthly installments starting 20 Jul 2025 and expire 20 Jun 2035.

What is Thomas D. Carey's total LAB share ownership after the reported transactions?

He beneficially owns 194,058 common shares directly following the grants.

Do the reported transactions involve any open-market purchases or sales of LAB stock?

No. The Form 4 only discloses equity awards (RSUs and options); no shares were bought or sold on the market.
STANDARD BIOTOOLS INC

NASDAQ:LAB

LAB Rankings

LAB Latest News

LAB Latest SEC Filings

LAB Stock Data

523.80M
373.92M
1.86%
73.11%
3.81%
Medical Devices
Laboratory Analytical Instruments
United States
SOUTH SAN FRANCISCO